ASCO, American Society of Clinical Oncology; BVZ, bevacizumab; Bevacizumab; CAT, computed axial tomography; CI, confidence interval; CPT11, irinotecan; CR, complete response; CTCAE, common terminology criteria for adverse events; FLAIR, fluid-attenuated inversion recovery; FSRT, fractionated stereotactic radiotherapy; Fractionated stereotactic radiotherapy; GTV, gross tumour volume; HGG, high-grade glioma; HR, hazard ratio; High-grade glioma; KPS, Karnofsky Performance Scale; MGMT, O-6-methylguanine-DNA methyltransferase; MRI, magnetic resonance imaging; NA, not applicable; OS, overall survival; PD, progressive disease; PET, positron emission tomography; PFS, progression-free survival; PR, partial response; PTV, planning target volume; RANO, revised Assessment in Neuro-Oncology; Rescue treatment; SD, stable disease; SEOM, Sociedad Española de Oncología Médica; SRS, stereotactic radiosurgery; TMZ, temozolomide; VEGF, vascular endothelial growth factor